{"entity":{"id":"paper-park-tils-untreated-early-tnbc-ann-oncol-2019","kind":"paper","name":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","aka":[],"tldr":"In 476 women with early triple-negative cancer who had no chemotherapy, more lymphocytes in the tumour still meant fewer relapses, and stage I patients with 30% or more had a 97% chance of no distant relapse at five years.","summary":"Individual data from 476 TNBC patients not treated with chemotherapy at four centres (1989 to 2015; median age 64, median tumour 1.6 cm, 83% node-negative) were pooled. Median sTILs were 10% (interquartile range 4 to 30%). In multivariable analysis each 10% increment gave hazard ratios of 0.90 (iDFS), 0.86 (D-DFS) and 0.88 (OS). Stage I patients with sTILs 30% or more (74) had five-year iDFS 91%, D-DFS 97% and OS 98%.","asOf":"2026-09-24","links":[{"label":"Park et al., Ann Oncol 2019: TILs in 476 early TNBC patients who received no chemotherapy","url":"https://doi.org/10.1093/annonc/mdz395"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31566659/"}],"tags":[],"related":[],"cancers":["tnbc","tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["tils"],"trials":[],"people":["loi-sherene","giuseppe-curigliano","fabrice-andre","kim-sung-bae"],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz395","pmid":"31566659","authors":"Park JH, Jonas SF, Bataillon G, et al.","paperType":"observational","findings":["Median sTILs 10% in untreated early TNBC.","Each 10% increment: iDFS HR 0.90, D-DFS 0.86, OS 0.88.","Stage I with sTILs 30% or more: five-year D-DFS 97%, OS 98%."],"whatItMeans":"TILs are prognostic without chemotherapy, which is what a de-escalation biomarker has to show before trials omit treatment on its basis.","caveats":["Retrospective, older and node-negative patients who were selected not to receive chemotherapy.","Only 74 patients in the stage I high-TIL group."],"changedPractice":false,"participants":476},"route":"/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"term":[{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/"}],"person":[{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/"},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/"},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/"},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/"}],"journal":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/"}]}}